1. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients
- Author
-
Ruigang Cai, Pin Zhang, Peng Yuan, Fei Ma, Qing Li, Yang Luo, Qiao Li, Jiayu Wang, Ying Fan, Guo Jihong, and Binghe Xu
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Lower risk ,Adjuvant therapy ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,breast cancer ,Trastuzumab ,Internal medicine ,HER2 ,medicine ,risk factors ,skin and connective tissue diseases ,Chemotherapy ,business.industry ,Hazard ratio ,Retrospective cohort study ,medicine.disease ,trastuzumab ,030220 oncology & carcinogenesis ,Cohort ,Original Article ,business ,medicine.drug - Abstract
Objective To assess the long-term effectiveness and safety of trastuzumab in adjuvant therapy for Chinese patients with early-stage human epidermal growth factor 2 (HER2)-positive breast cancer in a real-world setting. Methods This retrospective observational study analyzed the medical records of HER2-positive breast cancer patients between 2000 and 2012 at the Chinese Academy of Medical Sciences. Patients who received adjuvant chemotherapy alone or adjuvant chemotherapy followed by/combined with trastuzumab were included. The Kaplan-Meier method was used to estimate disease-free survival (DFS) and overall survival (OS). Hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated using the Cox regression model. Results Of the 1,348 patients analyzed, 909 received chemotherapy alone and 439 received chemotherapy plus trastuzumab. The 3-year, 5-year and 10-year DFS rates were 83.70%, 76.38% and 68.94%, respectively, in the chemotherapy-alone cohort, and 90.21%, 86.19% and 83.45% in the chemotherapy plus trastuzumab cohort. The 3-year, 5-year and 10-year OS rates were 96.10%, 91.40% and 81.88% in the chemotherapy-alone cohort, and 98.17%, 94.91% and 90.01% in the chemotherapy plus trastuzumab cohort. The chemotherapy plus trastuzumab group had a significantly lower risk of disease recurrence and death than the chemotherapy-alone group (DFS: HR=0.50, 95% CI, 0.37-0.68; P
- Published
- 2019